Global Retinoblastoma Treatment Market Study, 2019: Outlook to 2024 – Non-hereditary Retinoblastoma Expected to Maintain Its Dominance – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Retinoblastoma
Treatment Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.

Global Retinoblastoma Treatment market was valued at USD 2,297.13
million in 2018, and is estimated to be valued at USD 3,001.78 million
in 2024, witnessing a CAGR of 4.56%. Certain factors that are driving
the market growth include remission and the chance of recurrence, and
increasing public awareness.

Recurrent retinoblastoma occurs, when cancer comes back after it has
been treated and diagnosed. Both extraocular and intraocular
retinoblastoma might have probable chances of remittance.

Generally, the likelihood of relapse and formation of secondary tumors
increases with the genetic nature of the disease. Patients with
non-hereditary or sporadic retinoblastoma are not as susceptible to
relapse, as hereditary ones. Although, the cure rate for retinoblastoma
is quite high, the exact cure rate is dependent on the extent of the
disease and chances of recurrence. The increasing number of treatment
procedures drive the retinoblastoma treatment market.

In addition, improving awareness about retinoblastoma is a worthwhile
goal, and any eye complaint merits careful attention from all nursing
and medical personnel. Improving awareness regarding retinoblastoma is
especially important in developing countries, as the incidences of eye
cancer are increasing, and many children die undiagnosed or have
advanced disease at presentation, due to delay in referral to an
oncology centre. Retinoblastoma educational and public awareness
campaigns have been shown to increase referrals, decrease rates of
advanced disease, and improve outcomes in low and middle-income
countries.

However, side effects of retinoblastoma surgery, radiation therapy to
the head and certain chemotherapy drugs, such as cisplatin and
carboplatin (Paraplatin, Paraplatin AQ), may cause hearing loss when
they are given to very young children. The other eye problems include
difficulty in judging distance between objects and difficulty seeing to
the side (peripheral vision). Eye problems can also lead to changes in
balance.

Key Market Trends

Non-hereditary Retinoblastoma is Expected to Hold the Highest Market
Share in the Retinoblastoma Type Segment

In the Retinoblastoma type segment of the Retinoblastoma treatment
market, the non-hereditary retinoblastoma (NHR) is expected to have the
largest market size and is likely to witness a CAGR of 3.82% in the
forecast period.

Non-hereditary retinoblastoma (NHR), also known as sporadic
retinoblastoma, is the more prevalent form of retinoblastoma. According
to the American Cancer Society, 67% of reported cases (in the United
States) of retinoblastoma in pediatrics are non-hereditary or sporadic.

The NHR is mostly a pediatric disease, and according to the American
Cancer Society, the survival rates post diagnosis is approximately 90%.
According to the Union for International Cancer Control, the average
age-adjusted incidence rate of retinoblastoma in the United States and
Europe is 2-5/106 children (approximately one in 14,000 – 18,000 live
births).

The market for NHR is expected to grow tremendously over the forecast
period, primarily due to the higher incidence rate, when compared to
hereditary retinoblastoma. Additionally, factors, like high survival
rates post diagnosis in developed regions, like the United States, are
likely to add to the global market growth.

Asia-Pacific Dominates the Market and is Expected to Remain Dominant
During the Forecast Period

Asia-Pacific currently dominates the market for Retinoblastoma Treatment
and is expected to continue its strong hold for a few more years. This
region is expected to increase its market share in the future owing to
the fact that, retinoblastoma (Rb) is the most common primary
intraocular malignancy of infancy and childhood, and seriously endangers
the vision and life of children.

According to the United Nations Survey in 2016, China was only second to
that in India, in the prevalence of Rb in APAC countries. Similarly,
according to the Japanese Journal of Ophthalmology, in 2018, the average
occurrence frequency for retinoblastoma was 1:16,823 births/year and at
diagnosis, 89.0% of the patients were aged younger than 3 years and
41.0% were aged younger than 1 year.

Furthermore, in countries like India, current treatment modalities of
systemic chemotherapy and focal treatment have contributed significantly
to disability limitation and patient survival and there is less
knowledge on the genetics of the retinoblastoma gene and its protein,
and there is potential for developing targeted molecular therapies.

Competitive Landscape

The Retinoblastoma Treatment market is moderately competitive and
consists of a considerable number of major players. Companies like B
Baxter International Inc., GlaxoSmithKline, Pfizer Inc., Johnson &
Johnson, Novartis AG, Bristol-Myers Squibb, Merck & Co., Cadila
Pharmaceuticals, and Teva Pharmaceutical, among others, are expected to
hold the substantial market share in the Retinoblastoma Treatment market.

Various developments have recently been taking place in the market. For
example, in June 2018, GSK completed the Consumer Healthcare buyout of
Novartis.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Remission and the Chance of Recurrence

4.2.2 Increasing Public Awareness

4.3 Market Restraints

4.3.1 Small Patient Pool

4.3.2 Side Effects of Retinoblastoma Surgery

4.4 Porter’s Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Treatment Type

5.1.1 Surgery

5.1.2 Radiation therapy

5.1.3 Laser Therapy (Photocoagulation)

5.1.4 Cryotherapy

5.1.5 Thermotherapy

5.1.6 Chemotherapy

5.1.6.1 Carboplatin

5.1.6.2 Cisplatin

5.1.6.3 Vincristine

5.1.6.4 Etoposide

5.1.6.5 Cyclophosphamide

5.1.6.6 Topotecan

5.1.6.7 Doxorubicin

5.1.6.8 Cyclosporine

5.1.6.9 Melphalan

5.1.7 Opthalmic Artery Infusion Chemotherapy

5.1.8 High-dose Chemotherapy and Stem Cell Transplant

5.2 By Type of Retinoblastoma

5.2.1 Non-hereditary Retinoblastoma

5.2.2 Hereditary Retinoblastoma

5.3 By Type of Staging

5.3.1 Intraocular Retinoblastoma

5.3.2 Extraocular Retinoblastoma

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia Pacific

5.4.4 Middle East and Africa

5.4.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Baxter International Inc.

6.1.2 Bristol-Myers Squibb Company

6.1.3 Cadila Pharmaceuticals

6.1.4 GlaxoSmithKline PLC

6.1.5 Johnson & Johnson

6.1.6 Merck & Co.

6.1.7 Novartis AG

6.1.8 Pfizer Inc.

6.1.9 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/research/55dhd7/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs